A lack of secretory leukocyte protease inhibitor (SLPI) causes defects in granulocytic differentiation

Blood

Volumn 123, Issue 8, 2014, Pages 1239-1249

  Klimenkova, Olga ^a   Ellerbeck, Wienke ^a   Klimiankou, Maksim ^a   Ünalan, Murat ^a   Kandabarau, Siarhei ^a   Gigina, Anna ^a   Hussein, Kais ^a   Zeidler, Cornelia ^a   Welte, Karl ^a   Skokowa, Julia ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; LYMPHOID ENHANCER FACTOR 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; NUCLEAR FACTOR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SHORT HAIRPIN RNA; HAX1 PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOCYTE ELASTASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SLPI PROTEIN, HUMAN;

ARTICLE; BONE MARROW CELL; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; GRANULOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; MUTANT; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE; CELL STRAIN HEK293; CYTOLOGY; DNA MICROARRAY; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; NEUTROPENIA; PATHOLOGY; STEM CELL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BONE MARROW CELLS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; GRANULOCYTES; HEK293 CELLS; HUMANS; LEUKOCYTE ELASTASE; MAP KINASE SIGNALING SYSTEM; MYELOID CELLS; NEUTROPENIA; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; STEM CELLS;

EID: 84897008558     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-508887     Document Type: Article

References (50)

1. van Wetering S, van der Linden AC, van Sterkenburg MA, Rabe KF, Schalkwijk J, Hiemstra PS. Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase. J Investig Med. 2000;48(5):359-366.
2. Abe T, Kobayashi N, Yoshimura K, et al. Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J Clin Invest. 1991;87(6):2207-2215.
3. Seemüller U, Arnhold M, Fritz H, et al. The acid-stable proteinase inhibitor of human mucous secretions (HUSI-I, antileukoprotease). Complete amino acid sequence as revealed by protein and cDNA sequencing and structural homology to whey proteins and Red Sea turtle proteinase inhibitor. FEBS Lett. 1986;199(1):43-48. (Pubitemid 16072610)
4. Jacobsen LC, Sørensen OE, Cowland JB, Borregaard N, Theilgaard-Mönch K. The secretory leukocyte protease inhibitor (SLPI) and the secondary granule protein lactoferrin are synthesized in myelocytes, colocalize in subcellular fractions of neutrophils, and are coreleased by activated neutrophils. J Leukoc Biol. 2008;83(5):1155-1164. (Pubitemid 351960347)
5. Sallenave JM, Si Tahar M, Cox G, Chignard M, Gauldie J. Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils. J Leukoc Biol. 1997;61(6):695-702. (Pubitemid 27276061)
6. Williams SE, Brown TI, Roghanian A, Sallenave JM. SLPI and elafin: one glove, many fingers. Clin Sci (Lond). 2006;110(1):21-35. (Pubitemid 43059043)
7. Saitoh H, Masuda T, Shimura S, Fushimi T, Shirato K. Secretion and gene expression of secretory leukocyte protease inhibitor by human airway submucosal glands. Am J Physiol Lung Cell Mol Physiol. 2001;280(1):L79-L87.
8. Gauthier F, Fryksmark U, Ohlsson K, Bieth JG. Kinetics of the inhibition of leukocyte elastase by the bronchial inhibitor. Biochim Biophys Acta. 1982;700(2):178-183. (Pubitemid 12191635)
9. Dale DC, Person RE, Bolyard AA, et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood. 2000;96(7):2317-2322.
10. Welte K, Zeidler C, Dale DC. Severe congenital neutropenia. Semin Hematol. 2006;43(3):189-195. (Pubitemid 43963504)
11. Aprikyan AA, Kutyavin T, Stein S, et al. Cellular and molecular abnormalities in severe congenital neutropenia predisposing to leukemia. Exp Hematol. 2003;31(5):372-381. (Pubitemid 36579362)
12. Konishi N, Kobayashi M, Miyagawa S, Sato T, Katoh O, Ueda K. Defective proliferation of primitive myeloid progenitor cells in patients with severe congenital neutropenia. Blood. 1999;94(12):4077-4083.
13. Cario G, Skokowa J, Wang Z, et al. Heterogeneous expression pattern of pro- and anti-apoptotic factors in myeloid progenitor cells of patients with severe congenital neutropenia treated with granulocyte colony-stimulating factor. Br J Haematol. 2005;129(2):275-278. (Pubitemid 40562449)
14. Carlsson G, Aprikyan AA, Tehranchi R, et al. Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cells. Blood. 2004;103(9):3355-3361. (Pubitemid 38525664)
15. Köllner I, Sodeik B, Schreek S, et al. Mutations in neutrophil elastase causing congenital neutropenia lead to cytoplasmic protein accumulation and induction of the unfolded protein response. Blood. 2006;108(2):493-500. (Pubitemid 44061347)
16. Grenda DS, Murakami M, Ghatak J, et al. Mutations of the ELA2 gene found in patients with severe congenital neutropenia induce the unfolded protein response and cellular apoptosis. Blood. 2007;110(13):4179-4187. (Pubitemid 351377781)
17. Nanua S, Murakami M, Xia J, et al. Activation of the unfolded protein response is associated with impaired granulopoiesis in transgenic mice expressing mutant Elane. Blood. 2011;117(13): 3539-3547.
18. Skokowa J, Fobiwe JP, Dan L, Thakur BK, Welte K. Neutrophil elastase is severely down-regulated in severe congenital neutropenia independent of ELA2 or HAX1 mutations but dependent on LEF-1. Blood. 2009;114(14):3044-3051.
19. Skokowa J, Cario G, Uenalan M, et al. LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med. 2006;12(10):1191-1197. (Pubitemid 44527356)
20. Li FQ, Person RE, Takemaru K, et al. Lymphoid enhancer factor-1 links two hereditary leukemia syndromes through core-binding factor alpha regulation of ELA2. J Biol Chem. 2004;279(4):2873-2884. (Pubitemid 38114279)
21. Takahashi H, Nukiwa T, Basset P, Crystal RG. Myelomonocytic cell lineage expression of the neutrophil elastase gene. J Biol Chem. 1988;263(5):2543-2547. (Pubitemid 18060324)
22. El Ouriaghli F, Fujiwara H, Melenhorst JJ, Sconocchia G, Hensel N, Barrett AJ. Neutrophil elastase enzymatically antagonizes the in vitro action of G-CSF: implications for the regulation of granulopoiesis. Blood. 2003;101(5):1752-1758. (Pubitemid 36237570)
23. Hunter MG, Druhan LJ, Massullo PR, Avalos BR. Proteolytic cleavage of granulocyte colony-stimulating factor and its receptor by neutrophil elastase induces growth inhibition and decreased cell surface expression of the granulocyte colony-stimulating factor receptor. Am J Hematol. 2003;74(3):149-155. (Pubitemid 37363010)
24. Rao RM, Betz TV, Lamont DJ, et al. Elastase release by transmigrating neutrophils deactivates endothelial-bound SDF-1alpha and attenuates subsequent T lymphocyte transendothelial migration. J Exp Med. 2004;200(6):713-724. (Pubitemid 39299458)
25. Valenzuela-Fernández A, Planchenault T, Baleux F, et al. Leukocyte elastase negatively regulates Stromal cell-derived factor-1 (SDF-1)/CXCR4 binding and functions by amino-terminal processing of SDF-1 and CXCR4. J Biol Chem. 2002;277(18):15677-15689. (Pubitemid 34967841)
26. Fitch PM, Roghanian A, Howie SE, Sallenave JM. Human neutrophil elastase inhibitors in innate and adaptive immunity. Biochem Soc Trans. 2006;34(Pt 2):279-282.
27. Kawabata K, Hagio T, Matsuoka S. The role of neutrophil elastase in acute lung injury. Eur J Pharmacol. 2002;451(1):1-10. [Review]. (Pubitemid 35251839)
28. Wiedow O, Meyer-Hoffert U. Neutrophil serine proteases: potential key regulators of cell signalling during inflammation. J Intern Med. 2005;257(4):319-328. [Review]. (Pubitemid 40461184)
29. Sano C, Shimizu T, Tomioka H. Effects of secretory leukocyte protease inhibitor on the tumor necrosis factor-alpha production and NF-kappaB activation of lipopolysaccharide-stimulated macrophages. Cytokine. 2003;21(1):38-42. (Pubitemid 36369375)
30. Ma G, Greenwell-Wild T, Lei K, et al. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med. 2004;200(10):1337-1346. (Pubitemid 39552574)
31. Subramaniyam D, Hollander C, Westin U, Erjefält J, Stevens T, Janciauskiene S. Secretory leukocyte protease inhibitor inhibits neutrophil apoptosis. Respirology. 2011;16(2):300-307.
32. Taggart CC, Cryan SA, Weldon S, et al. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med. 2005;202(12):1659-1668. (Pubitemid 41815872)
33. Rasool N, LaRochelle W, Zhong H, Ara G, Cohen J, Kohn EC. Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells. Clin Cancer Res. 2010;16(2):600-609.
34. Jin FY, Nathan C, Radzioch D, Ding A. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell. 1997;88(3):417-426. (Pubitemid 27131383)
35. Kamezaki K, Shimoda K, Numata A, et al. Roles of Stat3 and ERK in G-CSF signaling. Stem Cells. 2005;23(2):252-263. (Pubitemid 40239520)
36. Akbarzadeh S, Ward AC, McPhee DO, Alexander WS, Lieschke GJ, Layton JE. Tyrosine residues of the granulocyte colony-stimulating factor receptor transmit proliferation and differentiation signals in murine bone marrow cells. Blood. 2002;99(3):879-887. (Pubitemid 34525549)
37. Zhang D, Simmen RC, Michel FJ, Zhao G, Vale-Cruz D, Simmen FA. Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes. J Biol Chem. 2002;277(33):29999-30009.
38. Kikuchi T, Abe T, Yaekashiwa M, et al. Secretory leukoprotease inhibitor augments hepatocyte growth factor production in human lung fibroblasts. Am J Respir Cell Mol Biol. 2000;23(3):364-370.
39. Skokowa J, Lan D, Thakur BK, et al. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(1)-sirtuin-1-dependent pathway. Nat Med. 2009;15(2):151-158.
40. Skokowa J, Klimiankou M, Klimenkova O, et al. Interactions among HCLS1, HAX1 and LEF-1 proteins are essential for G-CSF-triggered granulopoiesis. Nat Med. 2012;18(10):1550-1559.
41. Doulatov S, Notta F, Rice KL, et al. PLZF is a regulator of homeostatic and cytokine-induced myeloid development. Genes Dev. 2009;23(17):2076-2087.
42. Ohlsson K, Linder C, Lundberg E, Axelsson L. Release of cytokines and proteases from human peripheral blood mononuclear and polymorphonuclear cells following phagocytosis and LPS stimulation. Scand J Clin Lab Invest. 1996;56(5):461-470. (Pubitemid 26266012)
43. Sano C, Shimizu T, Sato K, Kawauchi H, Tomioka H. Effects of secretory leucocyte protease inhibitor on the production of the anti-inflammatory cytokines, IL-10 and transforming growth factor-beta (TGF-beta), by lipopolysaccharide-stimulated macrophages. Clin Exp Immunol. 2000;121(1):77-85. (Pubitemid 30436018)
44. Hoskins E, Rodriguez-Canales J, Hewitt SM, et al. Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells. Gynecol Oncol. 2011;122(3):656-662.
45. Zhang Y, DeWitt DL, McNeely TB, Wahl SM, Wahl LM. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest. 1997;99(5):894-900. (Pubitemid 27123626)
46. Ashcroft GS, Lei K, Jin W, et al. Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat Med. 2000;6(10):1147-1153.
47. Nakamura A, Mori Y, Hagiwara K, et al. Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. J Exp Med. 2003;197(5):669-674. (Pubitemid 36314661)
48. Wen J, Nikitakis NG, Chaisuparat R, et al. Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma. Am J Pathol. 2011;178(6):2866-2878.
49. Simpkins FA, Devoogdt NM, Rasool N, et al. The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells. Carcinogenesis. 2008;29(3):466-472. (Pubitemid 351404861)
50. Yang J, Zhu J, Sun D, Ding A. Suppression of macrophage responses to bacterial lipopolysaccharide (LPS) by secretory leukocyte protease inhibitor (SLPI) is independent of its antiprotease function. Biochim Biophys Acta. 2005;1745(3):310-317. (Pubitemid 41330785)